What Happened?
Shares of biotech company 10x Genomics (NASDAQ:TXG) jumped 6.1% in the morning session after Bank of America raised its price target on the stock to $80 from $50 while keeping a Neutral rating.
The firm cited improving sentiment, growing consumables revenue, and initial traction for the Atera platform as positive drivers for the business. Bank of America maintained its Neutral rating on the stock despite the higher price target. The firm pointed to hardware revenue volatility and operating losses as ongoing factors offsetting the progress in consumables revenue and the Atera platform.
Is now the time to buy 10x Genomics? Access our full analysis report here, it's free .
What Is The Market Telling Us
10x Genomics's shares are extremely volatile and have had 60 moves greater than 5% over the last year. In that context, today's move indicates the market considers this news meaningful but not something that would fundamentally change its perception of the business.
The previous big move we wrote about was 11 days ago when the stock gained 2.8% on the news that Argus analyst John Eade initiated coverage on the company with a Buy rating. The new coverage established Argus's formal research tracking of 10x Genomics. An analyst initiation occurs when an investment research firm begins publishing regular analysis and investment recommendations on a security.
A Buy rating indicates an expectation that the stock will deliver positive returns or outperform benchmark averages over an investment timeframe. New coverage initiations often draw increased attention from investors, contributing to positive trading momentum.
10x Genomics is up 391% since the beginning of the year, but at $81.59 per share, it is still trading 16.5% below its 52-week high of $97.74 from October 2026. Despite the year-to-date gain, investors who bought $1,000 worth of 10x Genomics's shares 5 years ago would now be looking at only $522.78.
ONE MORE THING: 3 Hidden Platforms Growing 3X Faster than Amazon, Google, and PayPal.Amazon, Google, and Meta all followed the same playbook: Dominate an ignored market. Build an unbeatable moat. Scale until you're unstoppable.
These three platforms are running that exact playbook right now. The early investors in Amazon made fortunes. The early investors in these could do the same. Get All 3 Stocks Here for FREE .
